Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.17
NSPH's Cash to Debt is ranked higher than
71% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. NSPH: 1.17 )
NSPH' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 1.17

Equity to Asset 0.50
NSPH's Equity to Asset is ranked higher than
62% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NSPH: 0.50 )
NSPH' s 10-Year Equity to Asset Range
Min: -5.28   Max: 0.94
Current: 0.5

-5.28
0.94
F-Score: 5
Z-Score: -18.04
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -283.63
NSPH's Operating margin (%) is ranked lower than
53% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. NSPH: -283.63 )
NSPH' s 10-Year Operating margin (%) Range
Min: -2890.06   Max: -337.14
Current: -283.63

-2890.06
-337.14
Net-margin (%) -294.53
NSPH's Net-margin (%) is ranked lower than
53% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. NSPH: -294.53 )
NSPH' s 10-Year Net-margin (%) Range
Min: -4551.67   Max: -346.4
Current: -294.53

-4551.67
-346.4
ROE (%) -112.25
NSPH's ROE (%) is ranked lower than
51% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. NSPH: -112.25 )
NSPH' s 10-Year ROE (%) Range
Min: -1493.55   Max: -39.64
Current: -112.25

-1493.55
-39.64
ROA (%) -75.35
NSPH's ROA (%) is ranked lower than
53% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. NSPH: -75.35 )
NSPH' s 10-Year ROA (%) Range
Min: -466.5   Max: -34.3
Current: -75.35

-466.5
-34.3
ROC (Joel Greenblatt) (%) -318.82
NSPH's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. NSPH: -318.82 )
NSPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -733.73   Max: -394.95
Current: -318.82

-733.73
-394.95
Revenue Growth (3Y)(%) 31.70
NSPH's Revenue Growth (3Y)(%) is ranked higher than
96% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NSPH: 31.70 )
NSPH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -73.2   Max: 49.9
Current: 31.7

-73.2
49.9
EBITDA Growth (3Y)(%) -28.10
NSPH's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. NSPH: -28.10 )
NSPH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 34.8
Current: -28.1

0
34.8
EPS Growth (3Y)(%) -27.30
NSPH's EPS Growth (3Y)(%) is ranked higher than
54% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. NSPH: -27.30 )
NSPH' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.8   Max: 48.1
Current: -27.3

-69.8
48.1
» NSPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NSPH Guru Trades in Q4 2013

John Keeley 26,000 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2014

NSPH Guru Trades in Q1 2014

John Keeley 26,000 sh (unchged)
» More
Q2 2014

NSPH Guru Trades in Q2 2014

Jim Simons 156,864 sh (New)
George Soros 58,000 sh (New)
John Keeley 26,000 sh (unchged)
» More
Q3 2014

NSPH Guru Trades in Q3 2014

John Keeley 26,000 sh (unchged)
George Soros Sold Out
Jim Simons 126,162 sh (-19.57%)
» More
» Details

Insider Trades

Latest Guru Trades with NSPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $0.557 - $1.69 $ 0.39-62%0
George Soros 2014-06-30 New Buy$1.23 - $2.25 $ 0.39-76%58000
John Keeley 2013-09-30 New Buy$1.83 - $3.44 $ 0.39-84%26000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
NSPH's P/B is ranked higher than
83% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. NSPH: 1.80 )
NSPH' s 10-Year P/B Range
Min: 0.82   Max: 7.31
Current: 1.8

0.82
7.31
P/S 2.10
NSPH's P/S is ranked higher than
76% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. NSPH: 2.10 )
NSPH' s 10-Year P/S Range
Min: 1.96   Max: 188.83
Current: 2.1

1.96
188.83
EV-to-EBIT -1.22
NSPH's EV-to-EBIT is ranked higher than
61% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. NSPH: -1.22 )
NSPH' s 10-Year EV-to-EBIT Range
Min: -6.4   Max: 0.1
Current: -1.22

-6.4
0.1
Current Ratio 2.59
NSPH's Current Ratio is ranked higher than
70% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. NSPH: 2.59 )
NSPH' s 10-Year Current Ratio Range
Min: 0.63   Max: 20.13
Current: 2.59

0.63
20.13
Quick Ratio 1.59
NSPH's Quick Ratio is ranked higher than
66% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. NSPH: 1.59 )
NSPH' s 10-Year Quick Ratio Range
Min: 0.61   Max: 19.52
Current: 1.59

0.61
19.52

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.00
NSPH's Price/Net Current Asset Value is ranked higher than
87% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NSPH: 10.00 )
NSPH' s 10-Year Price/Net Current Asset Value Range
Min: 1.02   Max: 14.25
Current: 10

1.02
14.25
Price/Tangible Book 2.11
NSPH's Price/Tangible Book is ranked higher than
86% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. NSPH: 2.11 )
NSPH' s 10-Year Price/Tangible Book Range
Min: 0.88   Max: 6.14
Current: 2.11

0.88
6.14
Price/Median PS Value 0.07
NSPH's Price/Median PS Value is ranked higher than
99% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. NSPH: 0.07 )
NSPH' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 4.56
Current: 0.07

0.1
4.56
Earnings Yield (Greenblatt) -84.10
NSPH's Earnings Yield (Greenblatt) is ranked lower than
55% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. NSPH: -84.10 )
NSPH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 801.1   Max: 3849.2
Current: -84.1

801.1
3849.2

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:3NS.Germany,
Nanosphere, Inc., was incorporated in 1999 in Delaware. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
» More Articles for NSPH

Headlines

Articles On GuruFocus.com
comment on NSPH Mar 02 2013 
NANOSPHERE, INC. Reports Operating Results (10-Q) Aug 05 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 06 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) Nov 05 2009 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Dec 23 2014
NANOSPHERE INC Financials Nov 18 2014
10-Q for Nanosphere, Inc. Nov 07 2014
Nanosphere Announces Third Quarter Financial and Operating Results Nov 05 2014
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 05 2014
Nanosphere Announces Third Quarter Financial and Operating Results Nov 05 2014
Q3 2014 NANOSPHERE INC Earnings Release - After Market Close Nov 05 2014
Nanosphere to Release Third Quarter Results and Host Investor Conference Call on Wednesday, November... Oct 28 2014
Nanosphere to Release Third Quarter Results and Host Investor Conference Call on Wednesday, November... Oct 28 2014
Nanosphere, Inc. Announces the Closing of Common Stock Offering Oct 27 2014
NANOSPHERE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Oct 27 2014
Nanosphere, Inc. Announces the Closing of Common Stock Offering Oct 27 2014
As earnings season heats up, stocks close on the lows… Oct 22 2014
Nanosphere Prices $20 Million Public Offering of Common Stock Oct 22 2014
NANOSPHERE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 22 2014
Nanosphere Prices $20 Million Public Offering of Common Stock Oct 22 2014
Nanosphere Announces Commencement of Public Offering of Common Stock; Preliminary Third Quarter 2014... Oct 21 2014
NANOSPHERE INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Results of... Oct 21 2014
Nanosphere Announces Commencement of Public Offering of Common Stock; Preliminary Third Quarter 2014... Oct 21 2014
Shire PLC Takes A Dive As AbbVie Reconsiders Offer Oct 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK